HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up

著者: Christian Jackisch, Roberto Hegg, Daniil Stroyakovskiy, Jin‐Seok Ahn, Bohuslav Melichar, Shin‐Cheh Chen, Sung‐Bae Kim, Mikhail Lichinitser, Elżbieta Starosławska, Georg Kunz, S. Falcon, Shou‐Tung Chen, A. Crepelle-Fléchais, Dominik Heinzmann, Mona Shing, Xavier Pivot - European Journal of Cancer 2016 被引用: 78